121 / 154
447
patients with central nervous system metastases of non-small
cell lung cancer. J Thorac Oncol 2010;5:950-5.
55. Wakeling AE, Guy SP, Woodburn JR, et al. ZD1839 (Iressa): an
orally active inhibitor of epidermal growth factor signaling with
potential for cancer therapy. Cancer Res 2002;62:5749-54.
56. Broniscer A, Panetta JC, O’Shaughnessy M, et al. Plasma and
cerebrospinal fluid pharmacokinetics of erlotinib and its active
metabolite OSI-420. Clin. Cancer Res 2007;13:1511–15.
57. Iuchi T, Shingyoji M, Sakaida T, et al. Phase II trial of gefitinib
alone without radiation therapy for Japanese patients with
brain metastases from EGFR-mutant lung adenocarcinoma.
Lung Cancer 2013;82:282-287.
58. Schuler M, Wu YL, Hirsh V, et al. First-Line Afatinib versus
Chemotherapy in Patients with Non-Small Cell Lung Cancer and
Common Epidermal Growth Factor Receptor Gene Mutations
and Brain Metastases. J. Thorac. Oncol 2016;11:380-90.
59. Hoffknecht P, Tufman A, Wehler T, et al. Efficacy of the irreversible
ErbB family blocker sperduafatinib in epidermal growth factor
receptor (EGFR) tyrosine kinase inhibitor (TKI)-pretreated
non-small-cell lung cancer patients with brain metastases or
leptomeningeal disease. J. Thorac. Oncol 2015;10:156-63.
60. Jänne PA, Yang JC, Kim DW, et al. AZD9291 in EGFR Inhibitor–
Resistant Non– Small-Cell Lung Cancer. N Engl J Med
2015;372:1689–99.
61. Ballard P, Yates JW, Yang Z, et al. Preclinical Comparison of
Osimertinib with Other EGFR-TKIs in EGFR-Mutant NSCLC
Brain Metastases Models, and Early Evidence of Clinical Brain
Metastases Activity. Clin. Cancer Res 2016;22:5130-40.
62. Soda M, Choi YL, Enomoto M, et al. Identification of the
transforming EML4-ALK fusion gene in non-small-cell lung
cancer. Nature 2007;448:561-6.
63. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma
kinase inhibition in non-small-cell lung cancer. N Engl J Med
2010;363;1693–1703.
64. Gainor JF, Varghese AM, Ou S, et al. ALK rearrangements are
mutually exclusive with mutations in EGFR or KRAS: an analysis
of 1,683 patients with non-small cell lung cancer. Clin Cancer
Res 2013;19:4273–81.
65. Pan Y, Zhang Y, Li Y, et al. ALK, ROS1 and RET fusions in 1139
lung adenocarcinomas: a comprehensive study of common
and fusion pattern-specific clinicopathologic, histologic and
cytologic features. Lung Cancer 2014;84:121–6.
66. Costa DB, Shaw AT, Ou SH, et al. Clinical Experience With
Crizotinib in Patients With Advanced ALK-Rearranged
Non-Small-Cell Lung Cancer and Brain Metastases. J Clin
Oncol 2015;33:1881–8.
67. Ou SH, Ahn JS, De Petris L, et al. Alectinib in Crizotinib-
Refractory ALK- Rearranged Non-Small-Cell Lung Cancer: A
Phase II Global Study. J Clin Oncol 2016;34:661-8.
68. Shaw AT, Gandhi L, Gadgeel S, et al. Alectinib in ALK-positive,
crizotinib-resistant,
non-small-cell
lung
cancer:
a
single-group, multicentre, phase 2 trial. Lancet Oncol
2016;17:234-42.
69. Gainor JF, Sherman CA, Willoughby K, et al. Alectinib
salvages CNS relapses in ALK-positive lung cancer patients
previously treated with crizotinib and ceritinib. J Thorac Oncol
2015;10:232–6.
70. Ou SH, Sommers KR, Azada MC, et al. Alectinib induces a
durable (
>
15 months) complete response in an ALK-positive
non-small cell lung cancer patient who progressed on crizotinib
with diffuse leptomeningeal carcinomatosis. Oncologist
2015;20;224–6.
71. Kodama T, Hasegawa M, Takanashi K, et al. Antitumor activity
of the selective ALK inhibitor alectinib in models of intracranial
metastases. Cancer Chemother Pharmacol 2014;74:1023-8.
72. Gadgeel SM, Gandhi L, Riely GJ, et al. Safety and activity of
alectinib against systemic disease and brainmetastases in
patients with crizotinibresistant ALK-rearranged non-small-
cell lung cancer (AF-002JG): results from the dose-finding
portion of a phase 1/2 study. Lancet Oncol 2014;15:1119-28.
73. Antonia SJ, López-Martin JA, Bendell J, et al. Nivolumab alone
and nivolumab plus ipilimumab in recurrent small-cell lung
cancer (CheckMate 032): a multicentre, open-label, phase 1/2
trial. Lancet Oncol 2016;17; 883–95.
74. Goldberg SB, Gettinger SN, Mahajan A, et al. Pembrolizumab
for patients with melanoma or non-small-cell lung cancer and
untreated brain metastases: early analysis of a nonrandomised,
open-label, phase 2 trial. Lancet Oncol 2016;17:976–83.
75. Meert AP, Paesmans M, Berghmans T, et al. Prophylactic cranial
irradiation in small cell lung cancer: a systematic review of the
literature with meta-analysis. BMC Cancer 2001;1:5.
76. Slotman, B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial
irradiation in extensive small-cell lung cancer. N Engl J Med
2007;357:664–72.
77. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P,
Sawaya RE. Incidence proportions of brain metastases in
patients diagnosed (1973 to 2001) in the Metropolitan Detroit
Cancer Surveillance System. J Clin Oncol 2004;22; 2865–72.
78. Tsukada Y, Fouad A, Pickren JW, Lane WW. Central nervous
system metastasis from breast carcinoma. Autopsy study.
Cancer 1983;52:2349–54.
79. Patanaphan V, Salazar OM, Risco R. Breast cancer: metastatic
patterns and their prognosis. South Med J 1988;81:1109–12.
80. Cho SY, Choi HY. Causes of death and metastatic patterns in
patients with mammary cancer. Ten-year autopsy study. Am J
Clin Pathol 1980;73: 232–4.
81. Hagemeister FB, Buzdar AU, Luna MA, Blumenschein GR.
Causes of death in breast cancer: a clinicopathologic study.
Cancer 1980;46:162–7.
82. Arvold ND, Oh KS, Niemierko A, et al. Brain metastases after
breast-conserving therapy and systemic therapy: incidence and
characteristics by biologic subtype. Breast Cancer Res. Treat.
2012;136:153–60.
83. Slimane K, Andre F, Delaloge S, et al. Risk factors for brain
relapse in patients with metastatic breast cancer. Ann. Oncol
2004;15;1640–4.
84. Pestalozzi BC, Zahrieh D, Price KN, et al. Identifying breast
cancer patients at risk for Central Nervous System (CNS)
[METÁSTASIS CEREBRALES: UNA MIRADA BIOLÓGICA Y CLÍNICA - Dr. Manuel Álvarez y cols.]